About AVT
Browse Articles
Customer Services

Original article

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis–HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study

Hadija H Semvua, Charles M Mtabho, Quirine Fillekes, Jossy van den Boogaard, Riziki M Kisonga, Liberate Mleoh, Arnold Ndaro, Elton R Kisanga, Andre van der Ven, Rob E Aarnoutse, Gibson S Kibiki, Martin J Boeree, David M Burger

Corresponding author name: Hadija H Semvua
Corresponding author e-mail: hadija.semvua@gmail.com

Citation: Antiviral Therapy 2013; 18:105-113
doi: 10.3851/IMP2413

Date accepted: 25 August 2012
Date published online: 05 October 2012


Background: To evaluate the effect of rifampicin-based tuberculosis (TB) treatment on the pharmacokinetics of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet, and vice versa, in Tanzanian TB–HIV-coinfected patients.

Methods: This was a Phase II open-label multiple dose pharmacokinetic and safety study. This study was conducted in TB–HIV-coinfected Tanzanian patients who started TB treatment (rifampicin/isoniazid/pyrazinamide/ethambutol) at week 1 to week 8 and continued with rifampicin and isoniazid for another 16 weeks. Antiretroviral treatment (ART) of efavirenz/tenofovir/emtricitabine in a fixed-dose combination tablet was started at week 4 after initiation of TB treatment. A 24-h pharmacokinetic sampling curve was recorded at week 8 (with TB treatment) and week 28 (ART alone). For TB drugs, blood samples at 2 and 5 h post-dose were taken at week 3 (TB treatment alone) and week 8 (with ART).

Results: A total of 25 patients (56% male) completed the study; 21 had evaluable pharmacokinetic profiles. The area under the concentration–time curve 0–24 h post-dose of efavirenz, tenofovir and emtricitabine were slightly higher when these drugs were coadministered with TB drugs; geometric mean ratios (90% CI) were 1.08 (0.90, 1.30), 1.13 (0.93, 1.38) and 1.05 (0.85, 1.29), respectively. For TB drugs, equivalence was suggested for peak plasma concentrations when administered with and without efavirenz/tenofovir/emtricitabine. Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported.

Conclusions: Coadministration of efavirenz, tenofovir and emtricitabine with a standard first-line TB treatment regimen did not significantly alter the pharmacokinetic parameters of these drugs and was tolerated well by Tanzanian TB patients who are coinfected with HIV.


Copyright © 2020 Nucleus Holdings Ltd. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.